Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer

Coleman, R, Woodward, E, Brown, J et al. (11 more authors) (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment, 127 (2). 429 - 438. ISSN 1573-7217

Abstract

Metadata

Authors/Creators:
  • Coleman, R
  • Woodward, E
  • Brown, J
  • Cameron, D
  • Bell, R
  • Dodwell, D
  • Keane, M
  • Gil, M
  • Davies, C
  • Burkinshaw, R
  • Houston, SJ
  • Grieve, RJ
  • Barrett-Lee, PJ
  • Thorpe, H
Keywords: Adult; aged; bone density conservation agents; breast neoplasms; chemotherapy, adjuvant; diphosphonates; female; humans; imidazoles; incidence; jaw diseases; middle aged; neoplasm staging; neoplasms, second primary; osteonecrosis; treatment outcome
Dates:
  • Published: June 2011
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Clinical Trials Research Unit (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 16 Apr 2015 11:44
Last Modified: 11 May 2015 17:25
Published Version: http://dx.doi.org/10.1007/s10549-011-1429-y
Status: Published
Publisher: Springer Verlag
Identification Number: https://doi.org/10.1007/s10549-011-1429-y

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics